134 related articles for article (PubMed ID: 35403848)
1. Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature.
Oliva A; Cancelli F; Brogi A; Curtolo A; Savelloni G; Siccardi G; Marcelli G; Mazzuti L; Ricci P; Turriziani O; Antonelli G; Venditti M; Mastroianni CM
New Microbiol; 2022 Jan; 45(1):62-72. PubMed ID: 35403848
[TBL] [Abstract][Full Text] [Related]
2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
3. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
4. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
5. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients.
Kasten MJ; Lahr BD; Parisapogu A; Yetmar ZA; O'Horo JC; Orenstein R; Moreno Franco P; Razonable RR; Vergidis P; Shah AS; Enzler MJ; Inwards DJ; Bauer PR
Sci Rep; 2023 Dec; 13(1):21249. PubMed ID: 38040756
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
[TBL] [Abstract][Full Text] [Related]
10. Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.
Gachoud D; Bertelli C; Rufer N
Br J Haematol; 2023 Jan; 200(2):e25-e27. PubMed ID: 36354067
[No Abstract] [Full Text] [Related]
11. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
12. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
14. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
16. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
17. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
18. Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague.
Bohoněk M; Řezáč D; Holub M
Cas Lek Cesk; 2020; 159(5):175-180. PubMed ID: 33297703
[TBL] [Abstract][Full Text] [Related]
19. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
[TBL] [Abstract][Full Text] [Related]
20. Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B-cell depleted patients with persistent COVID-19.
Inbar T; Dann EJ; Kerner O; Stern A
Transfusion; 2024 Mar; 64(3):443-448. PubMed ID: 38327238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
